REDWOOD CITY, CA--(Marketwired - Apr 4, 2016) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today results from a genomic substudy of the ...
It's been a difficult year for CardioDx, but there may be light at the end of the tunnel: In a new study, researchers found that the company's genetic test for coronary artery disease could help ...
PALO ALTO, CA--(Marketwired - Feb 26, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced a new publication on the economic utility of ...
PALO ALTO, CA--(Marketwired - Feb 3, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of a new analysis demonstrating ...
CLEVELAND, OH — The age/sex/gene-expression score (ASGES) test known as Corus CAD (CardioDx) appears easy to incorporate and effective in excluding obstructive coronary artery disease (CAD) in ...
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that Palmetto GBA, a national contractor that administers Medicare benefits, has established coverage for ...
Blood-Based Test Has Potential to Improve Quality of Care and Lower Costs of Evaluation of Obstructive Coronary Artery Disease REDWOOD CITY, Calif. – CardioDx, Inc., a molecular diagnostics company ...
REDWOOD CITY, CA--(Marketwired - Jul 7, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, confirmed today that Aetna has established a clinical policy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results